Cedars-Sinai Biomanufacturing Center
- Company typePrivate
- Founded-
- HeadquartersWest Hollywood, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Cedars-Sinai Biomanufacturing Center firmographics
Firmographics- Name
- Cedars-Sinai Biomanufacturing Center
- Legal name
- Cedars-Sinai Health System
- Website
- https://csbiomfg.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Cedars-Sinai Biomanufacturing Center industry classification
Industry- Product category
- Cell Therapy Biomanufacturing Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Banking & Viral Seed Services (MCB/WCB/VSB) (HLAGAGAD)
- akta.pro secondary industry
- Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA)
Keywords
Where Cedars-Sinai Biomanufacturing Center is headquartered
LocationHeadquarters
- HQ city
- West Hollywood
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Cedars-Sinai Biomanufacturing Center business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Others
Revenue model
- Cell Collection Products: Cell line product catalog offering iPSC lines, GMP iPSC lines, gene-modified iPSCs, neural cells, ESC lines available for order via online catalog with Material Transfer Agreement requirements.
- Research and GMP Services: Contract research services including custom iPSC generation, PSC quality control and characterization, PBMC isolation and processing, biobanking and PSC thawing, and GMP manufacturing and quality control services for IND-enabling clinical trials.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Cedars-Sinai Biomanufacturing Center product offering
Product offeringCore offering
Cedars-Sinai Biomanufacturing Center (CBC) is a 22,000 sq ft cGMP biomanufacturing facility that maintains one of the world's largest repositories of iPSCs, embryonic stem cells, gene-modified iPSCs, and differentiated cells, and provides contract research services (custom iPSC generation, PSC QC, PBMC processing, biobanking) along with cGMP-compliant manufacturing and quality control services for cell and gene therapy products intended for IND-enabling clinical trials.
Product overview
Cedars-Sinai Biomanufacturing Center (CBC) operates as a 22,000 square foot state-of-the-art biomanufacturing facility offering an integrated portfolio of stem cell products and contract research services. The core offering is its Cell Collection Repository—one of the world's largest repositories of iPSCs, embryonic stem cells, gene-modified iPSCs, and differentiated cells (including neural cells, endothelial cells, and motor neuron precursors). Supporting this repository are two main service lines: Research Services (custom iPSC generation using footprint-free reprogramming, PSC quality control and characterization, PBMC isolation and processing, and biobanking/PSC thawing) and GMP Services (cGMP manufacturing of cell and gene therapy products including MCBs/WCBs, iPSC-derived cells, gene-edited therapies, and immunotherapies; plus GMP quality control with characterization testing, sterility/mycoplasma/endotoxin testing, flow cytometry, and ddPCR). The facility contains seven ISO 7 cGMP cleanroom production suites and specialized equipment including CliniMACS Prodigy instruments and clinical-grade cell sorters.
Differentiator
Problem solved
Functional benefit
Products and services
- Cell Collection Repository One of the world's largest repositories of iPSCs, embryonic stem cells, gene-modified iPSCs, differentiated cells (including neural and endothelial cells), and related lines, available for order via online catalog and supplied under Material Transfer Agreement.
- Custom iPSC Generation Contract research service generating footprint-free induced pluripotent stem cells from human somatic tissues using non-integrating oriP/EBNA1 episomal plasmids.
- PSC Quality Control and Characterization Quality control and characterization testing services for pluripotent stem cell lines, including identity, viability, composition, activity, and stability assessments.
- PBMC Isolation and Processing PBMC isolation and processing services for downstream research and biobanking applications.
- Biobanking and PSC Thawing Biobanking services including stem cell banking, expansion of iPSC lines, and PSC thawing procedures.
- GMP Manufacturing Services cGMP-compliant biomanufacturing services for cell and gene therapy products, including manufacturing of MCBs and WCBs, autologous and allogeneic cell products, iPSC reprogramming, iPSC-derived cells, gene-edited therapies, retinal cells, cellular immunotherapies, NK cell therapies, and CAR T/TCR therapies, performed in seven ISO 7 cGMP cleanroom suites.
- GMP Quality Control Services GMP quality control services including cell bank characterization testing (identity, viability, composition, activity, stability), sterility, mycoplasma and endotoxin testing, flow cytometry, ddPCR, and custom QC method development and validation.
Quantifiable outcome
- One of the largest global repositories of induced pluripotent stem cells (iPSCs), embryonic stem cells, gene-modified iPSCs, and differentiated cells
- +1 more outcomes
Companies that use Cedars-Sinai Biomanufacturing Center
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Cedars-Sinai Biomanufacturing Center technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cedars-Sinai Biomanufacturing Center partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights6 records
Cedars-Sinai Biomanufacturing Center competitors and assessment
Company assessmentDirect peers
- BlueRock Therapeutics: Developer and manufacturer of iPSC-derived cell therapies, with engineered cell medicines for regenerative medicine. Most directly comparable as a specialized iPSC cell therapy developer with proprietary manufacturing capabilities.
- Century Therapeutics: Clinical-stage biotech developing iPSC-derived allogeneic cell therapies including CAR-T and NK cell programs. Comparable as a developer leveraging iPSC manufacturing for clinical-grade cell therapies.
- Roslin Cells (RoslinCT): Scottish CDMO specializing in iPSC-derived cell therapy manufacturing and clinical-grade cell banking. Directly comparable as a CDMO offering iPSC reprogramming, cell banking, and cGMP manufacturing services.
- WiCell (Wisconsin Cell Bank): Nonprofit stem cell bank and iPSC repository providing characterization and distribution services for academic and commercial clients. Directly comparable as a major iPSC repository and cell banking service.
Emerging players
- Cellares: Emerging cell therapy manufacturing company developing automated cell therapy manufacturing platforms. Comparable as a next-generation cell therapy manufacturing provider targeting biotech and academic clients.
- Cynata Therapeutics: Clinical-stage biotech developing iPSC-derived mesenchymal stem cell therapies. Comparable as a developer leveraging iPSC manufacturing for off-the-shelf cell therapy products.
Broad incumbents
- Lonza Cell & Gene Technologies: Global CDMO offering cell and gene therapy manufacturing services including iPSC-derived cell therapy production at industrial scale. Comparable as a cGMP cell therapy CDMO, but with far broader scale and global footprint than the Cedars-Sinai facility.
- Catalent Cell & Gene Therapy: Major CDMO providing cell therapy development, manufacturing, and analytical services. Directly comparable as a cGMP cell and gene therapy manufacturer serving biotech and academic clients with similar service portfolio.
- Thermo Fisher Scientific (Pharma Services / Patheon): Large-scale CDMO with cell and gene therapy manufacturing and viral vector services. Provides comparable cGMP manufacturing services but as part of a much broader pharma services portfolio.
Regional players
- Cell and Gene Therapy Catapult: UK-based cell and gene therapy accelerator with GMP manufacturing facilities and large-scale industrial centers. Comparable as a translational cell therapy CDMO but primarily serving UK and European markets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Cedars-Sinai Biomanufacturing Center social profiles
Digital presenceCedars-Sinai Biomanufacturing Center financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cedars-Sinai Biomanufacturing Center leadership team
Management profileNumber of profiles
Profiles11 records
Cedars-Sinai Biomanufacturing Center funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cedars-Sinai Biomanufacturing Center M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cedars-Sinai Biomanufacturing Center
What does Cedars-Sinai Biomanufacturing Center do?
Cedars-Sinai Biomanufacturing Center (CBC) is a 22,000 sq ft cGMP biomanufacturing facility that maintains one of the world's largest repositories of iPSCs, embryonic stem cells, gene-modified iPSCs, and differentiated cells, and provides contract research services (custom iPSC generation, PSC QC, PBMC processing, biobanking) along with cGMP-compliant manufacturing and quality control services for cell and gene therapy products intended for IND-enabling clinical trials.
Is Cedars-Sinai Biomanufacturing Center a public or private company?
Cedars-Sinai Biomanufacturing Center is a private company. It is classified as corporate owned and is currently operating.
When was Cedars-Sinai Biomanufacturing Center founded?
Cedars-Sinai Biomanufacturing Center was founded in -1. It employs 11 to 50 people.
Where is Cedars-Sinai Biomanufacturing Center based?
Cedars-Sinai Biomanufacturing Center is headquartered in West Hollywood, United States, in the North America region.
How does Cedars-Sinai Biomanufacturing Center make money?
Two revenue lines are on record. Cell Collection Products are the primary driver. The others are research and GMP Services.
Who are Cedars-Sinai Biomanufacturing Center's main competitors?
Direct peers on record are BlueRock Therapeutics, Century Therapeutics, Roslin Cells (RoslinCT) and WiCell (Wisconsin Cell Bank). Emerging players are Cellares and Cynata Therapeutics. Broad incumbents are Lonza Cell & Gene Technologies, Catalent Cell & Gene Therapy and Thermo Fisher Scientific (Pharma Services / Patheon). Cell and Gene Therapy Catapult is listed as a regional player.
Does Cedars-Sinai Biomanufacturing Center have an API?
No public API is recorded for Cedars-Sinai Biomanufacturing Center.
What industry is Cedars-Sinai Biomanufacturing Center in?
Cedars-Sinai Biomanufacturing Center's product category is Cell Therapy Biomanufacturing Services. Its primary akta.pro industry code is HLAGAGAD, Cell Banking & Viral Seed Services (MCB/WCB/VSB), with a secondary code of HLAFAAAA, Academic Medical Centers (AMCs) & Teaching Hospitals. Its NAICS code is 541714 and its SIC code is 2836.